Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eASC dose-escalation endotoxemia study in healthy volunteers
NL-OMON41050Phase 1Active, not recruiting
- Sponsor
- TiGenix
- Start
- Nov 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of expanded allogeneic adipose-derived mesenchymal stem cells in sepsis (4 arms), sponsored by TiGenix. Primary endpoint: Inflammatory response assessed by vital signs, symptoms, and laboratory measurements. Started Nov 2014; status: active, not recruiting.
02
Drugs
expanded allogeneic adipose-derived mesenchymal stem cells
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON41050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41050.